Back to News
Market Impact: 0.3
Alaunos Therapeutics, Inc. Announces Pricing of Registered Direct Offering priced at-the-market under Nasdaq rules
Source: GlobeNewswire
Healthcare & BiotechCapital Returns (Dividends / Buybacks)Company Fundamentals
Alaunos Therapeutics priced a public offering of common stock and pre-funded warrants to fund working capital and general corporate purposes. The financing improves near-term liquidity but is likely dilutive to existing shareholders, creating a modest negative share-price overhang.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.15
Ticker Sentiment
TCRT-0.35
More News
- Marvell to buy Lumentum in $115 billion deal in AI data-center bet
- Palantir reports booming U.S. commercial revenue growth, topping government for first time
- Anthropic releases amended IPO prospectus with third-quarter financials
- Coinbase has been battered over the past month. Morgan Stanley says steer clear
- The AI boom is facing another supply crunch. This time it’s the amount of capital available to feed Silicon Valley’s endless need for cash
- Anthropic to Spend $895 Billion in the Years Ahead